The overarching aim of the REMEDY center is to improve treatment of Rheumatic and Musculoskeletal Diseases (RMDs) by randomized clinical trials assessing novel treatment and treatment strategies, in combination with research and innovation to untangle RMD causes and characteristics.
ReMeDy received funding of 128 mill NOK from the Norwegian Research Council. The project starts Spring 2022 and will run for 8 years.
Diakonhjemmet Hospital in Oslo is the host institution, partnering with Oslo University Hospital, the University of Oslo, the MAGIC Evidence Ecosystem Foundation (MAGIC) and the Norwegian Rheumatism Association.
The seven work-packages (WPs) will approach the knowledge needs within RMD treatment from different angles, ensuring that the research results will benefit patients in all stages of the diseases. See figure for main objectives of the WPs.
The role of MAGIC in ReMeDy is to translate new research findings to clinical practice through BMJ Rapid Recommendations, also to be adapted and translated for national use and implementation.
MAGIC will also take part in related WPs to make sure the evidence production is fit for purpose for guideline development and use in clinical practice.
MAGIC is hiring a senior researcher to lead and coordinate this work, likely also to be linked to implementation research in the E3 project.